Nicotine Induces Resistance to Erlotinib Therapy in Non-Small-Cell Lung Cancer Cells Treated with Serum from Human Patients

被引:11
作者
Imabayashi, Tatsuya [1 ]
Uchino, Junji [1 ]
Osoreda, Hisayuki [2 ]
Tanimura, Keiko [1 ]
Chihara, Yusuke [1 ]
Tamiya, Nobuyo [1 ]
Kaneko, Yoshiko [1 ]
Yamada, Tadaaki [1 ]
Takayama, Koichi [1 ]
机构
[1] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Pulm Med, Kyoto 6020841, Japan
[2] Self Def Forces Fukuoka Hosp, Dept Internal Med, Fukuoka, Fukuoka 8160826, Japan
关键词
cotinine; nicotine; non-small-cell lung cancer (NSCLC); EGFR; erlotinib resistance; ACETYLCHOLINE-RECEPTORS; EGFR-TKI; SMOKING HISTORY; MULTIPLE ROLES; PROLIFERATION; GROWTH; GEFITINIB; ANGIOGENESIS; INHIBITION; METABOLISM;
D O I
10.3390/cancers11030282
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Previously, we reported that nicotine reduces erlotinib sensitivity in a xenograft model of PC9, an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI)-sensitive non-small-cell lung cancer cell line. The present study examined whether smoking induces erlotinib resistance in vitro. We assessed resistance to EGFR-TKIs by treating cancer cell lines with erlotinib, afatinib, or osimertinib, and serum collected from smokers within 30 min of smoking and that from a non-smoker as a control. We also assessed erlotinib resistance by treating PC9 cells exposed to serum from a smoker or a non-smoker, or serum from an erlotinib user. Treatment of the cancer cell lines with serum from smokers induced significant erlotinib resistance, compared with the control (p < 0.05). Furthermore, serum samples with a high concentration of cotinine (a nicotine exposure indicator) demonstrated stronger erlotinib resistance than those with low concentrations. Similar to the observations with erlotinib treatment of cell lines, the analysis of serum from erlotinib users revealed that smokers demonstrated significantly reduced sensitivity to erlotinib (p < 0.001). In conclusion, our present results support the hypothesis that smoking contributes to resistance to erlotinib therapy in non-small-cell lung cancer.
引用
收藏
页数:11
相关论文
共 37 条
[1]   Role of non-neuronal nicotinic acetylcholine receptors in angiogenesis [J].
Arias, Hugo R. ;
Richards, Victoria E. ;
Nga, David ;
Ghafoori, Mary E. ;
Le, Vanique ;
Mousa, Shaker A. .
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2009, 41 (07) :1441-1451
[2]   Heavy and light cigarette smokers have similar dysfunction of endothelial vasoregulatory activity - An in vivo and in vitro correlation [J].
Barua, RS ;
Ambrose, JA ;
Eales-Reynolds, LJ ;
DeVoe, MC ;
Zervas, JG ;
Saha, DC .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 39 (11) :1758-1763
[3]  
Benowitz Neal L, 2009, Handb Exp Pharmacol, P29, DOI 10.1007/978-3-540-69248-5_2
[4]   METABOLISM OF NICOTINE TO COTININE STUDIED BY A DUAL STABLE-ISOTOPE METHOD [J].
BENOWITZ, NL ;
JACOB, P .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 56 (05) :483-493
[5]   Nicotine activates cell-signaling pathways through muscle-type and neuronal nicotinic acetylcholine receptors in non-small cell lung cancer cells [J].
Carlisle, Diane L. ;
Liu, Xuwan ;
Hopkins, Toni M. ;
Swick, Michelle C. ;
Dhir, Rajiv ;
Siegfried, Jill M. .
PULMONARY PHARMACOLOGY & THERAPEUTICS, 2007, 20 (06) :629-641
[6]   Smoking Cessation: An Integral Part of Lung Cancer Treatment [J].
Cataldo, Janine K. ;
Dubey, Sarita ;
Prochaska, Jodi J. .
ONCOLOGY, 2010, 78 (5-6) :289-301
[7]   Multiple roles of nicotine on cell proliferation and inhibition of apoptosis: Implications on lung carcinogenesis [J].
Catassi, A. ;
Servent, D. ;
Paleari, L. ;
Cesario, A. ;
Russo, P. .
MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH, 2008, 659 (03) :221-231
[8]   Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: Subset analysis from the ISEL study [J].
Chang, Alex ;
Parikh, Purvish ;
Thongprasert, Sumitra ;
Tan, Eng Huat ;
Perng, Reury- Perng ;
Ganzon, Domingo ;
Yang, Chih-Hsin ;
Tsao, Chao-Jung ;
Watkins, Claire ;
Botwood, Nick ;
Thatcher, Nick .
JOURNAL OF THORACIC ONCOLOGY, 2006, 1 (08) :847-855
[9]   Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21 [J].
Clark, Gary M. ;
Zborowski, Denni M. ;
Santabarbara, Pedro ;
Ding, Keyue ;
Whitehead, Marlo ;
Seymour, Lesley ;
Shepherd, Frances A. .
CLINICAL LUNG CANCER, 2006, 7 (06) :389-394
[10]   The current situation:: Erlotinib (Tarceva®) and gefitinib (Iressa®) in non-small cell lung cancer [J].
Comis, RL .
ONCOLOGIST, 2005, 10 (07) :467-470